Short Seller Alert : Adamis Pharmaceuticals Corp (NASDAQ:ADMP).
An investigation on behalf of buyers of Adamis Pharmaceuticals Corp shares about likely securities legislation violations by Adamis Prescribed drugs and sure of its directors and officers in link particular economical statements was announced.
The investigation by a law firm focuses on feasible statements on behalf of purchasers of the securities of Adamis Pharmaceuticals Corp regarding irrespective of whether a sequence of statements by Adamis Pharmaceuticals about its small business, its prospects and its operations have been materially bogus and misleading at the time they were being produced.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Adamis Pharmaceuticals Corp concerning whether a series of statements by Adamis Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On March 27, 2015, Adamis Prescribed drugs Corp declared that it had been given a Full Reaction Letter from the U.S. Food & Drug Administration ("Fda") regarding the Firm's New Drug Application ("NDA") for its Epinephrine Injection USP one:a thousand .3mg Pre-crammed One Dose Syringe, or the Epinephrine PFS, product, for the emergency procedure of acute anaphylaxis, which is a extreme allergic response.
According to Adamis Prescribed drugs Corp on May perhaps 28, 2014, it submitted an NDA to the Fda pursuant to Part 505(b)(2) of the Food items, Drug & Cosmetic Act, as amended, for acceptance of the Epinephrine PFS merchandise. The Epinephrine PFS provides a premeasured dose of ephinephrine for the emergency remedy of anaphylaxis.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.